title: From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?
abstract: AD (Alzheimer's disease) is the most prevalent form of dementia in the aged population. Definitive diagnosis of AD is based on the presence of senile plaques and neurofibrillary tangles that are identified in post-mortem brain specimens. A third pathological component is inflammation. AD results from multiple genetic and environmental risk factors. Among other factors, epidemiological studies report beneficial effects of caffeine, a non-selective antagonist of adenosine receptors. In the present review, we discuss the impact of caffeine and the adenosinergic system in AD pathology as well as consequences in terms of pathology and therapeutics.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Flaten
authors.forename: Cyril
authors.initials: C
authors.lastname: Laurent
authors.affiliation: ‡Instituto de Medicina Molecular, Faculdade de Medicina Universidade de Lisboa, Lisbon, Portugal.
authors.forename: Joana E
authors.initials: JE
authors.lastname: Coelho
authors.affiliation: §Legacy Research Institute, Portland, OR 97232, U.S.A.
authors.forename: Ursula
authors.initials: U
authors.lastname: Sandau
authors.affiliation: ‡Instituto de Medicina Molecular, Faculdade de Medicina Universidade de Lisboa, Lisbon, Portugal.
authors.forename: Vânia L
authors.initials: VL
authors.lastname: Batalha
authors.forename: Sylvie
authors.initials: S
authors.lastname: Burnouf
authors.forename: Malika
authors.initials: M
authors.lastname: Hamdane
authors.forename: Sandrine
authors.initials: S
authors.lastname: Humez
authors.affiliation: §Legacy Research Institute, Portland, OR 97232, U.S.A.
authors.forename: Detlev
authors.initials: D
authors.lastname: Boison
authors.affiliation: ‡Instituto de Medicina Molecular, Faculdade de Medicina Universidade de Lisboa, Lisbon, Portugal.
authors.forename: Luísa V
authors.initials: LV
authors.lastname: Lopes
authors.forename: Luc
authors.initials: L
authors.lastname: Buée
authors.forename: David
authors.initials: D
authors.lastname: Blum
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism*; D000818:Animals; D002110:Caffeine / Q000627:therapeutic use*; D006801:Humans; D058915:Purinergic P1 Receptor Antagonists / Q000627:therapeutic use*; D018047:Receptors, Purinergic P1 / Q000378:metabolism
chemical_list: D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1; D002110:Caffeine